Related by context. All words. (Click for frequent words.) 63 Progression 61 disease progression 53 telomere shortening 52 maturation 50 progress 49 Thrombotic thromboembolic complications 49 Median progression 49 tumor regressions 49 arterial thickening 49 bone metastasis 49 cognitive decline 48 blastic phase 48 VEGF inhibition 48 hepatic fibrosis 48 liver fibrosis 48 hormone refractory 47 radiographic progression 47 advancement 47 regression 47 osteoclast activity 47 diabetic kidney 47 tumor progression 47 fibrosis 46 lung metastasis 46 clinically meaningful improvements 46 MAO B 46 progession 46 neuronal dysfunction 46 tau pathology 46 tumor shrinkage 46 lung fibrosis 46 mTOR inhibition 46 virologic response 45 SUTENT 45 progressions 45 urate levels 45 motor neuron degeneration 45 androgen receptor signaling 45 relapsing remitting 45 Prognostic factors 45 neurodegeneration 45 neurologic progression 45 bone resorption 45 CFTR inhibitors 45 BRAF inhibitor 45 tumor regression 45 NSCL cancer 45 MS relapses 45 biochemical recurrence 45 fibrotic disease 45 progressing 45 tumor recurrence 45 linear progression 45 PSADT 45 plasma uric acid 44 ADAGIO study 44 progression TTP 44 Free Survival PFS 44 clinically meaningful improvement 44 MDS AML 44 demyelinating 44 gas leak Gailius 44 nerve degeneration 44 onset 44 antibody mediated 44 anti leukemic 44 ANAVEX #-# [001] 44 neuro degeneration 44 presymptomatic 44 androgen deprivation 44 AGILECT R 44 leakiness 44 OMAPRO 44 degeneration 44 evolution 44 tumor regrowth 44 abiraterone 44 pre malignant lesions 44 Diamyd ® 44 AML acute myeloid 44 Diamyd r vaccine 44 PHD2 44 atherosclerotic disease 44 virologic responses 44 axitinib 44 cellular senescence 44 liver metastasis 44 amyloid formation 44 follicular Non Hodgkin 44 kinase inhibition 44 repolarization 44 elevated IOP 44 fibrotic 44 airway remodeling 44 elacytarabine 43 renal fibrosis 43 PRESEPT study 43 bavituximab monotherapy trial 43 intima media thickness 43 neuronal degeneration 43 neuroprotective therapies 43 transgene expression 43 regress 43 pharmacologic intervention 43 Pharmacokinetic studies 43 Symadex 43 schizophrenia CIAS 43 liver histology 43 viral replication 43 neurological degeneration 43 IGF 1R 43 abnormal glucose metabolism 43 Chronic pancreatitis 43 PAOD 43 Dose escalation 43 Garcia Manero 43 neovascularization 43 DXL# 43 RNFL thickness 43 Scale EDSS 43 sJIA 43 activated microglia 43 bone metastases 43 relapsed refractory 43 brain atrophy 43 demyelination 42 TGF beta signaling 42 sustained virologic response 42 prostate cancer CaP 42 remyelination 42 ALSFRS R 42 recurrent ovarian 42 cartilage degeneration 42 induced angiogenesis 42 progressed 42 bronchial airway 42 carotid IMT 42 anticancer activity 42 CR CRu 42 heavily pretreated 42 amyloid deposition 42 evaluable patients 42 Cyclin D1 42 prospectively stratified 42 pathophysiological mechanisms 42 prognostic significance 42 Akt activation 42 paclitaxel poliglumex 42 glycosylated hemoglobin HbA1c 42 indolent NHL 42 urate lowering 42 Avastin Tarceva 42 surgical debulking 42 graft occlusion 42 collagen degradation 42 following antiestrogen therapy 42 PDE7B 42 vidofludimus 42 levodopa therapy 42 vasodilatation 42 locoregional disease 42 HCV replication 42 IL 1ß 42 relapsing MS 42 cabazitaxel 42 amyloid plaque formation 42 Korsakoff 42 distant metastasis 42 erythropoiesis 42 symptomology 42 pomalidomide 42 MAPK pathway 42 etanercept 42 poststroke 42 pazopanib 42 Alzhemed TM 42 nonalcoholic steatohepatitis NASH 42 Sustained Virological Response 42 prolongs survival 42 HAQ DI 42 intact parathyroid hormone 42 ONCONASE R 42 choroidal neovascularization 42 proliferative retinopathy 42 TNF α 42 osteopontin 42 EBV infection 42 T1c 42 ASONEP 42 CTGF 42 antiangiogenic therapy 42 serum phosphate 42 Tmax 42 anti angiogenic therapy 42 CIMZIA ™ 42 indolent lymphomas 42 fibrosis progression 42 hedgehog signaling 42 MS CDMS 42 squalamine 42 Archexin 42 otelixizumab 42 fatty infiltration 42 CIMZIA TM 42 pCR 42 BR.# study 42 multitargeted 42 ulcer healing 42 CCR1 42 locoregional recurrence 41 Aplidin 41 aberrant activation 41 hippocampal atrophy 41 HER2 overexpression 41 vivo potency 41 abiraterone acetate 41 stratifying patients 41 beta1 41 overt nephropathy 41 systemic inflammation 41 conventional DMARDs 41 Inhaled nitric oxide 41 trastuzumab Herceptin ® 41 immune modulating 41 leukaemic stem cells 41 ACZ# 41 mg kg dose 41 SCr 41 BN# [004] 41 neuroprotective effects 41 adipogenic 41 choroidal neovascularization CNV 41 KIACTA ™ 41 chronicity 41 progresses 41 Peutz Jeghers syndrome 41 virological failure 41 CaM kinase II 41 antiangiogenic 41 DSMB recommended 41 Kaplan Meier 41 telomerase activity 41 ERK5 41 cataract formation 41 cardiotoxic effects 41 nonsense mutation 41 prognostic indicator 41 prednisone prednisolone 41 B lymphocyte 41 virologic failure 41 APOE genotype 41 bowel resection 41 complete cytogenetic response 41 carbohydrate absorption 41 TNF alpha 41 prognostic indicators 41 durable remissions 41 CEACAM1 41 carcinoids 41 hematological relapse 41 natriuretic peptide 41 atherogenesis 41 heavily pretreated patients 41 antithrombotic therapy 41 molecular determinants 41 psychosocial variables 41 TroVax ® 41 HER2 positive metastatic breast 41 prostate cancer metastases 41 PITX2 methylation 41 TTR amyloidosis 41 atherosclerotic coronary 41 smoldering multiple myeloma 41 oblimersen 41 protein biosynthesis 41 activin 41 relapsed AML 41 retinal ganglion cell 41 serum ALT 41 intratumoral 41 hematological indications 41 obatoclax 41 tumor histology 41 amyloid pathology 41 synaptogenesis 41 atherosclerotic 41 Aß 41 alagebrium 41 immune reconstitution 41 decompensated cirrhosis 41 variceal bleeding 41 histologic 41 Cogane 41 atherosclerosis 41 riociguat 41 maturational 41 mutated KRAS 41 HCV RNA 41 microglial activation 41 IFN α 41 hyperinsulinemia 41 serum parathyroid hormone 41 liver metastases 41 lintuzumab 41 progressive degeneration 41 hematologic toxicity 41 relapsed MCL 41 neurocognitive deficits 41 cytogenetic response 41 response pCR 41 metastatic disease 41 EDSS scores 40 biochemical relapse 40 remission CR 40 virological response 40 Bcl xL 40 CNV lesion 40 pathologic 40 Notch1 40 taxane chemotherapy administered 40 apo E 40 complete remissions 40 asymptomatic AF 40 DACH platinum 40 leukemic stem cells 40 akinesia 40 glufosfamide 40 HIV RNA 40 imatinib therapy 40 antitumor efficacy 40 resorption 40 cortical excitability 40 cisplatin chemotherapy 40 nephrogenic 40 pulmonary metastasis 40 prostate tumor 40 metastasis 40 acute lymphoblastic 40 differentiated thyroid 40 LRRK2 mutations 40 BNC# 40 CA4P 40 hepatic encephalopathy HE 40 colorectal carcinoma 40 virologic suppression 40 lowering blood glucose 40 lactate dehydrogenase 40 neurocognitive function 40 pro gress 40 ErbB2 positive 40 endostatin 40 diabetic nephropathy 40 RECIST criteria 40 previously untreated follicular 40 osteoblast activity 40 IV NSCLC 40 shortened telomeres 40 forodesine 40 ERK activation 40 antitumor effect 40 atopic march 40 PSA nadir 40 DAC HYP 40 Alzheimer Disease AD 40 PCa 40 chemosensitivity 40 axonal 40 regressing 40 fibrinolysis 40 microalbuminuria 40 postoperative radiotherapy 40 SSc 40 inflammatory lesions 40 undetectable HCV RNA 40 leukemic cell 40 ERK signaling 40 suppresses tumor 40 malignant transformation 40 platelet clumping 40 retinal pigment epithelial 40 CMV infections 40 inhibition 40 GAMMAGARD 40 FasL 40 Insulin PH# 40 EGFR mutation status 40 SUVmax 40 Nuvion 40 DMARD 40 rheumatoid arthritis RA 40 chemoradiotherapy 40 baminercept 40 ATL# [001] 40 malignant phenotype 40 teriflunomide 40 FDG uptake 40 TMEM density 40 TMEM#B 40 recanalization 40 tumor subtype 40 abrupt cessation 40 Flurizan 40 myelination 40 recurrent glioblastoma 40 orthodontic tooth 40 acute leukemias 40 HQK 40 smooth muscle myosin 40 aP2 40 dose escalation 40 T1a 40 SCEI manufactures 40 refractory metastatic 40 TNFα 40 histological 40 Hydroxyurea 40 onsets 40 Subgroup analysis 40 immunosuppressive regimen 40 anti apoptotic proteins 40 CINQUIL 40 severely impairs 40 fosbretabulin 40 serum urate levels 40 RAPAFLO R 40 E selectin 40 Kras mutation 40 platelet inhibition 40 neural degeneration 40 brain shrinkage 40 axonal damage 40 aMCI 40 locoregional 40 proliferative diabetic retinopathy 40 FTY# 40 BEXXAR therapeutic regimen 40 amnestic MCI 40 lipid synthesis 40 refractory CTCL 40 oncogenes genes 40 Apoptone 40 inhaled tobramycin 40 octreotide implant 40 CSF biomarkers 40 neuromotor 40 DAS# remission 40 diabetic retinopathy DR 40 metabolic dysregulation 40 C1 INH deficiency 40 timepoint 40 premalignant lesions 40 androgen hormone 40 laterality 40 hormone receptor status 40 serum HCV RNA 40 Natalizumab 40 premature senescence 40 serum PTH 40 chemotherapy docetaxel 40 subclinical disease 40 IFN γ 40 TGF β 40 subclinical atherosclerosis 40 mitoxantrone 40 cognitive impairment 40 adalimumab 40 ispinesib administered 40 Campath alemtuzumab 40 glutamate neurotransmission 40 sunitinib 40 prostate cancer PCa 40 antifungal therapy 40 plus MTX 40 PXD# 40 Medullary thyroid cancer 40 enzymatic activity 40 amyloid accumulation 39 uptake 39 neoadjuvant treatment 39 INCB# [001] 39 quantitative EEG 39 molecular underpinnings 39 Laquinimod 39 #beta HSD1 39 relapsing remitting multiple sclerosis 39 atheroma volume 39 Accumetrics VerifyNow System 39 R0 resection 39 CRp 39 neovascular 39 hematological toxicity 39 RRMS patients 39 relapsed MM 39 allergic airway inflammation 39 oncogenesis 39 p# activation 39 lorvotuzumab mertansine 39 median PFS 39 pressure natriuresis 39 PSN# [002] 39 CBLC# 39 PROSTVAC VF 39 Chronic lymphocytic leukemia CLL 39 alvespimycin 39 IV malignant melanoma 39 retinal dysfunction 39 Alzheimer pathology 39 neuroregenerative 39 coronary artery atherosclerosis 39 nodal metastasis 39 Akt inhibitor 39 histologic subtype 39 BIBW 39 HBeAg negative 39 TNFalpha 39 Stargardt Macular Dystrophy 39 MMP inhibitors 39 renin inhibition 39 spontaneous regression 39 GST pi 39 aminotransferase levels 39 androgen suppression 39 antiapoptotic 39 growth hormone secretion 39 endothelial dysfunction 39 HER2 expression 39 EGFr 39 angiogenesis inhibition 39 potentiation 39 postural stability 39 taxane chemotherapy 39 podocyte 39 annualized relapse 39 telomere lengths 39 olmesartan 39 prognostic biomarker 39 carcinoid 39 tocilizumab 39 serum phosphate levels 39 excitotoxic 39 HuMax EGFr 39 chromosomal rearrangement 39 T2DM 39 colorectal adenoma 39 androgen ablation 39 evolvement 39 VEGF induced 39 nestin expression 39 HuLuc# 39 brivaracetam 39 biochemical abnormalities 39 macroalbuminuria 39 stage IIIA 39 receptor tyrosine kinase inhibitor 39 neurogenesis 39 circulatory dysfunction 39 baroreflex 39 oncogenic mutations 39 atherothrombotic 39 cyclin E 39 gene amplification 39 dirucotide 39 airway hyperresponsiveness 39 antiestrogen 39 mRS 39 HGS# 39 vasculopathy 39 clinicopathological 39 MICARDIS ® 39 QRS duration 39 LHRH agonist 39 HIV HCV coinfected 39 nonsignificant trend 39 genomic biomarker 39 plaque buildup 39 visceral metastases 39 mammary tumor formation 39 Dysregulation 39 urinary excretion 39 refractory colorectal cancer 39 Kaplan Meier curve 39 tumor resection 39 Leydig cell 39 allograft rejection 39 trabedersen 39 prognostic marker 39 brain lesions 39 Myriad Flurizan 39 neuronal apoptosis 39 urothelial carcinoma 39 sporadic ALS 39 NOX4 39 oral FTY# 39 vessel constriction 39 samalizumab 39 intravascular hemolysis 39 IMC A# 39 R#/MEM # 39 antiangiogenic agents 39 intravenous dosing 39 engraftment 39 EGFR TKI 39 demonstrated antitumor activity 39 galanin 39 complete cytogenetic 39 chronologic 39 bosentan 39 Dasatinib 39 FTLD 39 SOCS2 39 α synuclein 39 airflow obstruction 39 erythropoietic 39 HNSCC 39 pertuzumab 39 pretreatment serum 39 Trovax 39 prognostic variables 39 p = #.# [002] 39 Chronic myeloid leukemia 39 LHRH analogues 39 leukemia AML 39 minimally symptomatic 39 Rasagiline 39 pathological hallmark 39 debulking surgery 39 muscular degeneration 39 Q#IR 39 GSK3B 39 imexon 39 LV hypertrophy 39 neoadjuvant chemotherapy 39 Polish archaeologists excavating 39 pathogenetic 39 induce apoptosis 39 lesional 39 muscular dystrophy cystic fibrosis 39 mg/m2 dose 39 secondary hyperparathyroidism 39 mediated inhibition 39 EGFR mutation positive 39 replicative 39 Capesaris 39 PEDF 39 PSA kinetics 39 anti Xa 39 neuron degeneration 39 tamoxifen therapy 39 beta amyloid peptide 39 cardiovascular calcification 39 genomic instability 39 diabetic gastroparesis 39 metastatic malignant melanoma 39 tumor necrosis 39 beta adrenergic receptor 39 acute myelogenous leukemia AML 39 IIa trials 39 cediranib 39 renal flares 39 cerebral ischemia 39 lymphatic vessel 39 muscle degeneration 39 CCR3 39 myocardial ischemia 39 Diabetic neuropathy 39 JP-#/fipamezole 39 BPH benign prostatic 39 serum HBV DNA 39 mammary tumors 39 Cardiac myosin activators 39 hippocampal neurogenesis 39 hedgehog pathway 39 lactate dehydrogenase LDH 39 phase IIb study 39 COX2 39 clinically meaningful reductions 39 Hsp# inhibition 39 urothelial bladder cancer 39 neuropathological 39 antidiabetic therapy 38 SERCA2a 38 glucose homeostasis 38 pathway 38 virologic 38 IL 7R 38 glioblastoma tumors 38 generalized seizures 38 intracellular signal transduction 38 flow mediated dilation 38 intraventricular 38 Phase Ib clinical 38 IFN gamma 38 Kaplan Meier analysis 38 genotypic resistance 38 receptor inhibitor 38 TRO# 38 pAkt 38 imatinib resistance 38 figitumumab 38 Abeta# 38 fibrogenesis 38 peripheral neuropathy 38 viral suppression 38 PEG SN# 38 breast irradiation APBI 38 dyssynchrony 38 alkylating agent 38 beta amyloid accumulation 38 demethylation 38 Eliezer Zomer Ph.D. 38 inhibit platelet aggregation 38 arteriosclerotic 38 lumiliximab 38 HER2 positive cancers 38 Lung transplantation 38 Raf MEK ERK 38 telomeres shorten 38 metastatic renal cell carcinoma 38 CD# upregulation 38 tissue oxygenation 38 chemoresistant 38 therapeutic armamentarium 38 Prestara 38 ossification 38 idarubicin 38 NLX P# 38 mitochondrial fusion 38 progressive neurodegenerative disorder 38 rindopepimut 38 Kinoid 38 erlotinib Tarceva 38 advanced carcinoid 38 TACI Ig 38 dosage regimens 38 TKM ApoB 38 parkinsonism 38 leukemia ALL 38 anemia neutropenia 38 atheromatous 38 T2D 38 metastatic renal 38 HBeAg 38 combinability 38 leukocyte count 38 pelvic lymphadenectomy 38 platelet aggregation 38 interstitium 38 haemodynamic 38 carotid artery thickness 38 FTIs 38 non squamous histology 38 cardiac allograft vasculopathy 38 telomere length 38 pro apoptotic 38 Lorianne Masuoka MD 38 myocardial reperfusion 38 Genetic predisposition 38 Troxatyl 38 exacerbations 38 steroidogenesis 38 neuronal function 38 caspase activation 38 fenretinide 38 nonfatal MI 38 CTEPH 38 talactoferrin 38 CCR2 antagonists 38 optimal dosing regimens 38 plasma kallikrein 38 carcinoid tumors 38 BEXXAR Therapeutic Regimen 38 pulmonary exacerbations 38 epigenetic mechanisms 38 nonmetastatic 38 SFRP1 38 glucagon receptor 38 ß1 38 DAPT 38 Sarcopenia 38 rituximab refractory 38 glycemia 38 dietary modification 38 microvascular dysfunction 38 multiple myeloma MM 38 eniluracil 38 Diabetic nephropathy 38 tramiprosate Alzhemed TM 38 arterial calcification 38 amyloid peptide 38 glycated hemoglobin levels 38 castration resistant prostate cancer 38 Secondary endpoints include 38 immunosuppressive regimens 38 CD4 + cell 38 tissue fibrosis 38 relapse 38 clinically localized prostate 38 Sgk1 38 osteosarcomas 38 choroidal vasculopathy 38 angiographically 38 5-FU/LV 38 colorectal carcinogenesis 38 muscarinic 38 CR nPR 38 idiopathic thrombocytopenic purpura 38 radiographic outcomes 38 Alu RNA 38 autophagic 38 Partial Response 38 HBeAg positive 38 osteogenic differentiation 38 immunostaining 38 Phase 2a trial 38 baseline A1C 38 experimental allergic encephalomyelitis 38 neurologic symptoms 38 NAT2 38 DNA adducts 38 schizotypal traits 38 APOPTONE 38 IFN beta 38 leukocyte adhesion 38 methotrexate therapy 38 mRNA expression 38 etiologic 38 intermittent dosing 38 cintredekin besudotox 38 KRAS wild 38 CYP#D# genotype 38 tezampanel NGX# 38 tHcy 38 chemoresistance 38 lymph node metastasis 38 amyloid β 38 brain metastases 38 inherited neurodegenerative 38 B7 H3 38 dyskeratosis congenita 38 Myelodysplastic Syndrome MDS 38 beta1 integrin 38 CLL 38 downregulation 38 CytoFab ™ 38 antitumour 38 neuronal differentiation 38 enzastaurin 38 Acute leukemia 38 prognostically 38 ZD# [001] 38 metastatic sarcomas 38 nonalcoholic steatohepatitis 38 protein tyrosine phosphatase 38 symptomatic intracranial hemorrhage 38 MSMB 38 CCyR 38 small lymphocytic lymphoma 38 oral methylnaltrexone 38 EGS# 38 adenoma recurrence 38 fluoropyrimidine 38 rhIL 7 38 Fibrillex TM 38 inotropic 38 IRX 2 38 phytoestrogen intake 38 nitazoxanide 38 recurrent glioblastoma multiforme 38 alanine aminotransferase ALT 38 Bevacizumab 38 hematologic malignancy 38 hyperalgesia 38 alveolar rhabdomyosarcoma 38 decrements 38 cecal intubation 38 putative biomarkers 38 XL# administered orally 38 multi factorial disease 38 contractile function 38 pegylated liposomal doxorubicin 38 decitabine 38 low dose cytarabine 38 IntroductionThe 38 corrected QT interval 38 Aβ 38 hour bronchodilation 38 artery stenosis 38 response CCyR 38 metabolic parameters 38 methotrexate monotherapy 38 interferon beta 38 Oxidative damage 38 premorbid 38 GATA3 38 intensive statin therapy 38 ischemia induced 38 chemopreventive agent 38 inflammatory biomarkers 38 NPC 1C 38 indibulin 38 Secondary endpoints included 38 fatal neuromuscular 38 Bezielle 38 tau tangles 38 androgen therapy 38 lumen diameter 38 preoperative PSA 38 malignant pleural mesothelioma 38 elotuzumab 38 amyloid deposits 38 randomized Phase 2b 38 diagnose Alzheimer disease 38 YONDELIS 38 ZOLINZA 38 Cytarabine Liposome Injection 38 pain palliation 38 chronic lymphocytic leukemia CLL 38 serum testosterone 38 lung function 38 Stage IIB 38 EGFR mutations 38 contractility 38 tanespimycin 38 EGFR HER 38 peroxidation 38 PEGylated interferon beta 1a 38 viral kinetics 38 atherosclerotic lesions 38 suppress viral replication 38 electrical conduction 38 HDACi 38 Ets2 38 tesmilifene Phase III 38 ventricular remodeling 38 viral titers 38 cardiac dysfunction 38 S#A# [002] 38 registrational 38 prognostic factor 38 cardiac repolarization 38 overactivity 38 CaP 38 paclitaxel Taxol 38 virological suppression 38 mammographic density 38 Sjögren syndrome 38 androgen blockade 38 SVR# 38 dose titration 38 progess 38 relapsed ovarian cancer 38 aortic regurgitation 38 randomized Phase IIb 38 prostate carcinogenesis 38 β cell 38 potent antiretroviral therapy 38 hematopoietic malignancies 38 β catenin 38 β amyloid 38 gastric atrophy 38 curability 38 Leukemia lymphoma 38 H. pylori eradication 38 breast cancer metastasis 38 cardiac hypertrophy 38 prospectively defined 38 concurrent chemoradiation 38 plasma viremia 38 neovascular AMD 38 multicenter Phase II 38 BPH symptoms 38 EDEMA3 trial 38 receptor internalization 38 endocannabinoid signaling 38 lenalidomide dexamethasone 38 immunotherapeutic approaches 38 neurologic disorder 38 ubiquitination 38 angiogenesis inhibitor 38 mutant KRAS 38 untreated psychosis 38 mesenchymal transition 38 CIN3 38 intestinal permeability 38 FOLFIRINOX 37 symptomatic AF 37 progeria rare 37 timepoints 37 dacetuzumab 37 dosing cohort 37 LCP AtorFen 37 claudication 37 disease progression TTP 37 surrogate endpoint 37 lipid peroxidation 37 skeletal sarcomere activator 37 mild cognitive 37 hepatocellular carcinoma 37 diabetic retinopathy